human dr3 fc chimera  (R&D Systems)

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: TL1A-DR3 plasma levels are predictive of HIV-1 disease control, and DR3 co-stimulation boosts HIV-1-specific T-cell responses

doi: 10.4049/jimmunol.2000933

Figure Lengend Snippet: sTL1A (A) and sDR3 (B) relative plasma levels (Z-score “communicome” values) in HIV-High (n=47) and HIV-Low (n=49) (Table S1). C-D) Gene expression (Table S1) of TL1A (C) and DR3 (D) in HIV-High (n=16) and HIV-Low (n=30). E-F) Unrelated validation cohorts for gene expression of TL1A (E) and DR3 (F) in dry pellet PBMC samples from seronegatives (SN, n=6) and HIV-infected individuals one year before and after initiation of treatment (untreated [n=11] and treated [n=5]) and in LTNP (n=23) (Table S1). G) Absolute DR3 quantifications in plasma (ELISA) in a confirmatory cohort including seronegatives (SN, n=8) and samples from time points one year before and after initiation of treatment (untreated [n=15] and treated [n=10]) and controllers (n=31), Table S1). The Mann-Whitney test was applied for group comparisons, and p-values < 0.05 were considered significant.

Article Snippet: Then, we co-stimulated the cells with 100 ng/ml of sTL1A (Recombinant Human TL1A/TNFSF15, R&D systems), 500 ng/ml of sDR3 (Recombinant Human DR3/TNFRSF25 Fc Chimera Protein, R&D systems), and /or 100 ng/ml of mAb anti-DR3 (Purified anti-human DR3 (TRAMP) JD3, Biolegend).

Techniques: Clinical Proteomics, Gene Expression, Biomarker Discovery, Infection, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: TL1A-DR3 plasma levels are predictive of HIV-1 disease control, and DR3 co-stimulation boosts HIV-1-specific T-cell responses

doi: 10.4049/jimmunol.2000933

Figure Lengend Snippet: A-B) sDR3 relative plasma levels (Z-score communicome) correlate with T-cell breadth (A) and magnitude (B) of HIV-High (n=46) and HIV-Low (n=41) individuals (Table S1). C) IFN-g-ELISPOT (percentage increase in the magnitude of T-cell) after HIV-specific peptide pool stimulation in the presence of recombinant TL1A and DR3 and specific anti-DR3 mAb in PBMCs from untreated PLWH (Table S1). D) Percentage increase in the magnitude of CEF-specific responses upon co-stimulation with anti-DR3 mAb. E) Increase in magnitude of DNA.HTI-specific T cell responses in isolated splenocytes from HTI-vaccinated mice after stimulation with the mouse DR3 specific antibody 4C12 (agonist DR3). The Spearman rank test was used for correlation analysis and the Wilcoxon signed rank test for group comparisons. p-values <0.05 were considered statistically significant.

Article Snippet: Then, we co-stimulated the cells with 100 ng/ml of sTL1A (Recombinant Human TL1A/TNFSF15, R&D systems), 500 ng/ml of sDR3 (Recombinant Human DR3/TNFRSF25 Fc Chimera Protein, R&D systems), and /or 100 ng/ml of mAb anti-DR3 (Purified anti-human DR3 (TRAMP) JD3, Biolegend).

Techniques: Clinical Proteomics, Enzyme-linked Immunospot, Recombinant, Isolation